dc.creatorWintjens, René
dc.creatorMakha Bifani, Amanda
dc.creatorBifani, Pablo
dc.date.accessioned2020-09-17T21:51:35Z
dc.date.accessioned2022-09-23T18:46:21Z
dc.date.available2020-09-17T21:51:35Z
dc.date.available2022-09-23T18:46:21Z
dc.date.created2020-09-17T21:51:35Z
dc.identifier2059-0105
dc.identifierhttps://doi.org/10.1038/s41541-020-00237-9
dc.identifierhttp://hdl.handle.net/20.500.12010/13396
dc.identifierhttps://doi.org/10.1038/s41541-020-00237-9
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3507112
dc.description.abstractThe SARS-CoV-2 outbreak originated in China in late 2019 and has since spread to pandemic proportions. Diagnostics, therapeutics and vaccines are urgently needed. We model the trimeric Spike protein, including flexible loops and all N-glycosylation sites, in order to elucidate accessible epitopes for antibody-based diagnostics, therapeutics and vaccine development. Based on published experimental data, six homogeneous glycosylation patterns and two heterogeneous ones were used for the analysis. The glycan chains alter the accessible surface areas on the S-protein, impeding antibody-antigen recognition. In presence of glycan, epitopes on the S1 subunit, that notably contains the receptor binding domain, remain mostly accessible to antibodies while those present on the S2 subunit are predominantly inaccessible. We identify 28 B-cell epitopes in the Spike structure and group them as nonaffected by the glycan cloud versus those which are strongly masked by the glycan cloud, resulting in a list of favourable epitopes as targets for vaccine development, antibody-based therapy and diagnostics.
dc.languageeng
dc.publishernpj vaccines
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectSARS-CoV-2
dc.subjectSpike protein
dc.subjectB-cell
dc.subjectGlycan cloud
dc.titleImpact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein


Este ítem pertenece a la siguiente institución